1. Home
  2. DGNX vs ANIP Comparison

DGNX vs ANIP Comparison

Compare DGNX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DGNX
  • ANIP
  • Stock Information
  • Founded
  • DGNX 2018
  • ANIP 2001
  • Country
  • DGNX United Kingdom
  • ANIP United States
  • Employees
  • DGNX N/A
  • ANIP N/A
  • Industry
  • DGNX
  • ANIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • DGNX
  • ANIP Health Care
  • Exchange
  • DGNX NYSE
  • ANIP Nasdaq
  • Market Cap
  • DGNX 1.2B
  • ANIP 1.5B
  • IPO Year
  • DGNX 2025
  • ANIP N/A
  • Fundamental
  • Price
  • DGNX $57.51
  • ANIP $71.53
  • Analyst Decision
  • DGNX
  • ANIP Strong Buy
  • Analyst Count
  • DGNX 0
  • ANIP 8
  • Target Price
  • DGNX N/A
  • ANIP $80.13
  • AVG Volume (30 Days)
  • DGNX 37.7K
  • ANIP 387.2K
  • Earning Date
  • DGNX 01-01-0001
  • ANIP 05-09-2025
  • Dividend Yield
  • DGNX N/A
  • ANIP N/A
  • EPS Growth
  • DGNX N/A
  • ANIP N/A
  • EPS
  • DGNX N/A
  • ANIP N/A
  • Revenue
  • DGNX $1,177,066.00
  • ANIP $614,376,000.00
  • Revenue This Year
  • DGNX N/A
  • ANIP $27.68
  • Revenue Next Year
  • DGNX N/A
  • ANIP $7.74
  • P/E Ratio
  • DGNX N/A
  • ANIP N/A
  • Revenue Growth
  • DGNX N/A
  • ANIP 26.20
  • 52 Week Low
  • DGNX $3.60
  • ANIP $52.50
  • 52 Week High
  • DGNX $155.00
  • ANIP $73.72
  • Technical
  • Relative Strength Index (RSI)
  • DGNX N/A
  • ANIP 59.87
  • Support Level
  • DGNX N/A
  • ANIP $68.50
  • Resistance Level
  • DGNX N/A
  • ANIP $73.72
  • Average True Range (ATR)
  • DGNX 0.00
  • ANIP 2.29
  • MACD
  • DGNX 0.00
  • ANIP -0.08
  • Stochastic Oscillator
  • DGNX 0.00
  • ANIP 64.22

About DGNX DIGINEX LIMITED

Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: